Tom John, Medical Oncologist and Translational Researcher at Peter MacCallum Cancer Centre, shared on X:
“Congratulations Jacob Sands on excellent presentation of DeLLphi-305. Impressive results with a deserved standing ovation.
Addition of Tarlatamab results in major improved OS. Increased AEs but as expected and not major. New SoC.”
You can also read: DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
